Fakhraldeen, M., Mostafa, H. (2018). Anticarbohydrate antibodies in patients with inflammatory bowel disease.. The Egyptian Journal of Hospital Medicine, 39(1), 260-267. doi: 10.21608/ejhm.2018.16969
Mohammed Fakhraldeen; Huseen Saad Mostafa. "Anticarbohydrate antibodies in patients with inflammatory bowel disease.". The Egyptian Journal of Hospital Medicine, 39, 1, 2018, 260-267. doi: 10.21608/ejhm.2018.16969
Fakhraldeen, M., Mostafa, H. (2018). 'Anticarbohydrate antibodies in patients with inflammatory bowel disease.', The Egyptian Journal of Hospital Medicine, 39(1), pp. 260-267. doi: 10.21608/ejhm.2018.16969
Fakhraldeen, M., Mostafa, H. Anticarbohydrate antibodies in patients with inflammatory bowel disease.. The Egyptian Journal of Hospital Medicine, 2018; 39(1): 260-267. doi: 10.21608/ejhm.2018.16969
Anticarbohydrate antibodies in patients with inflammatory bowel disease.
1Lecturer of internal medicine, Faculty of medicine, Mansoura University
2Consultant clinical pathology, King Fahd hospital, Riyadh, Saudi Arabia
Abstract
Evaluating antilaminaribioside carbohydrate antibodies (ALCA), antimannobioside carbohydrate antibodies (AMCA) and anti-Saccharomyces cerevisiae antibodies (ASCA), in patients with inflammatory bowel disease (IBD). Subjects and methods: 268 serum samples were used; 115 Crohn’s disease (CD), 83 ulcerative colitis, and 70 healthy control samples. All samples were evaluated using enzyme-linked immunosorbent assay for the following four anticarbohydrate antibodies: ACCA, ALCA, AMCA, and ASCA. Results: In patients with Crohn’s disease the prevalence of the anticarbohydrate antibodies was: ASCA 69%, AMCA 32%, ACCA 28% and ALCA 24% with the highest prevalence being for ASCA (P-value<0.0001) while in patients with ulcerative colitis the prevalence was: ACCA 46%, AMCA 35%, ALCA 23% and ASCA 15% with the highest prevalence being for ACCA (P- value<0.001). Conclusion: Anticarbohydrate antibodies are significantly present in patients with IBD. The use of a panel of anticarbohydrate antibodies may provide additional help in distinguishing IBD from non-IBD disease patterns and narrow the range of differential diagnosis in these patients.